Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jun;34(3):605-19.
doi: 10.1007/s10545-011-9308-6. Epub 2011 Mar 29.

Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies

Johannes M F G Aerts  1 , Wouter W Kallemeijn, Wouter Wegdam, Maria Joao Ferraz, Marielle J van Breemen, Nick Dekker, Gertjan Kramer, Ben J Poorthuis, Johanna E M Groener, Josanne Cox-Brinkman, Saskia M Rombach, Carla E M Hollak, Gabor E Linthorst, Martin D Witte, Henrik Gold, Gijs A van der Marel, Herman S Overkleeft, Rolf G Boot
Affiliations
Review

Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies

Johannes M F G Aerts et al. J Inherit Metab Dis. 2011 Jun.

Abstract

A biomarker is an analyte indicating the presence of a biological process linked to the clinical manifestations and outcome of a particular disease. In the case of lysosomal storage disorders (LSDs), primary and secondary accumulating metabolites or proteins specifically secreted by storage cells are good candidates for biomarkers. Clinical applications of biomarkers are found in improved diagnosis, monitoring disease progression, and assessing therapeutic correction. These are illustrated by reviewing the discovery and use of biomarkers for Gaucher disease and Fabry disease. In addition, recently developed chemical tools allowing specific visualization of enzymatically active lysosomal glucocerebrosidase are described. Such probes, coined inhibodies, offer entirely new possibilities for more sophisticated molecular diagnosis, enzyme replacement therapy monitoring, and fundamental research.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Gaucher cell accumulating the glycosphingolipid glucosylceramide and specifically secreting the biomarker chitotriosidase that can be detected in plasma. Example of corrections in plasma chitotriosidase in Gaucher disease patients receiving enzyme replacement therapy
See this image and copyright information in PMC

References

    1. Aerts JM, Hollak CE. Plasma and metabolic abnormalities in Gaucher's disease. Baillières Clin Haematol. 1997;10:691–709. - PubMed
    1. Aerts JM, Donker-Koopman WE, van der Vliet MK, Jonsson LM, Ginns EI, Murray GJ, Barranger JA, Tager JM, Schram AW. The occurrence of two immunologically distinguishable beta-glucocerebrosidases in human spleen. Eur J Biochem. 1985;150(3):565–574. - PubMed
    1. Aerts JM, Donker-Koopman WE, Murray GJ, Barranger JA, Tager JM, Schram AW. A procedure for the rapid purification in high yield of human glucocerebrosidase using immunoaffinity chromatography with monoclonal antibodies. Anal Biochem. 1986;154:655–663. - PubMed
    1. Aerts JM, Donker-Koopman WE, Koot M, Barranger JA, Tager JM, Schram AW. Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease. Clin Chim Acta. 1986;158:155–163. - PubMed
    1. Aerts JM, Schram AW, Strijland A, van Weely S, Jonsson LM, Tager JM, Sorrell SH, Ginns EI, Barranger JA, Murray GJ. Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation. Biochim Biophys Acta. 1988;964:303–308. - PubMed

MeSH terms

LinkOut - more resources